OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies.
Abramowicz
D
D
Nephrology Department, Hopital Erasme, Brussels, Belgium.
Norman
D J
DJ
Goldman
M
M
De Pauw
L
L
Kinnaert
P
P
Kahana
L
L
Thistlethwaite
J R
JR
Shield
C F
CF
Monaco
A P
AP
Vanherweghem
J L
JL
D000206:Actuarial Analysis; D001379:Azathioprine / Q000627:therapeutic use; D001530:Belgium; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000276:immunology / Q000502:physiology*; D006684:HLA-DR Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007511:Ischemia; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009926:Organ Preservation; D015996:Survival Rate; D014481:United States
D006684:HLA-DR Antigens; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine